Dual MEK/AKT inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS-mutant and wild-type melanoma

被引：50

作者：

Algazi, Alain P. ^{[1
]}

Esteve-Puig, Rosaura ^{[2
]}

Nosrati, Adi ^{[2
]}

Hinds, Brian ^{[3
]}

Hobbs-Muthukumar, Adele ^{[1
]}

Nandoskar, Prachi ^{[1
]}

Ortiz-Urda, Susana ^{[2
]}

Chapman, Paul B. ^{[4
]}

Daud, Adil ^{[1
]}

机构：

[1] UCSF Melanoma Oncol, San Francisco, CA 94143 USA

[2] UCSF Dermatol, San Francisco, CA USA

[3] UCSD Dermatopathol, La Jolla, CA USA

[4] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

来源：

PIGMENT CELL & MELANOMA RESEARCH | 2018年 / 31卷 / 01期

关键词：

AKT; GSK2141795; MEK; melanoma; NRAS; trametinib; wild type; UVEAL MELANOMA; SURVIVAL; BRAF; ASSOCIATION; COMBINATION; TUMORS;

D O I：

10.1111/pcmr.12644

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aberrant MAPK and PI3K pathway signaling may drive the malignant phenotype in NRAS-mutant and BRAF(WT) NRAS(WT) metastatic melanoma. To target these pathways, NRAS-mutant and BRAF(WT) NRAS(WT) patients received oral trametinib at 1.5mg daily and GSK2141795 at 50mg daily in a two-cohort Simon two-stage design. Participants had adequate end-organ function and no more than two prior treatment regimens. Imaging assessments were performed at 8-week intervals. A total of 10 NRAS-mutant and 10 BRAF(WT) NRAS(WT) patients were enrolled. No objective responses were noted in either cohort. The median PFS and OS were 2.3 and 4.0 months in the NRAS-mutant cohort and 2.8 and 3.5 months in the wild-type cohort. Grade 3 and grade 4 adverse events, primarily rash, were observed in 25% of patients. We conclude that the combination of trametinib and GSK2141795 does not have significant clinical activity in NRAS-mutant or BRAF(WT) NRAS(WT) melanoma.

引用

页码：110 / 114

页数：5

共 18 条

[1] Clinical Outcomes in Metastatic Uveal Melanoma Treated With PD-1 and PD-L1 Antibodies [J].

Algazi, Alain P. ;

Tsai, Katy K. ;

Shoushtari, Alexander N. ;

Munhoz, Rodrigo R. ;

Eroglu, Zeynep ;

Piulats, Josep M. ;

Ott, Patrick A. ;

Johnson, Douglas B. ;

Hwang, Jimmy ;

Daud, Adil I. ;

Sosman, Jeffrey A. ;

Carvajal, Richard D. ;

Chmielowski, Bartosz ;

Postow, Michael A. ;

Weber, Jeffrey S. ;

Sullivan, Ryan J. .

CANCER, 2016, 122 (21) :3344-3353

[2] MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study [J].

Ascierto, Paolo A. ;

Schadendorf, Dirk ;

Berking, Carola ;

Agarwala, Sanjiv S. ;

van Herpen, Carla M. L. ;

Queirolo, Paola ;

Blank, Christian U. ;

Hauschild, Axel ;

Beck, J. Thaddeus ;

St-Pierre, Annie ;

Niazi, Faiz ;

Wandel, Simon ;

Peters, Malte ;

Zubel, Angela ;

Dummer, Reinhard .

LANCET ONCOLOGY, 2013, 14 (03) :249-256

[3] A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors [J].

Bedard, Philippe L. ;

Tabernero, Josep ;

Janku, Filip ;

Wainberg, Zev A. ;

Paz-Ares, Luis ;

Vansteenkiste, Johan ;

Van Cutsem, Eric ;

Perez-Garcia, Jose ;

Stathis, Anastasios ;

Britten, Carolyn D. ;

Le, Ngocdiep ;

Carter, Kirsten ;

Demanse, David ;

Csonka, Denes ;

Peters, Malte ;

Zubel, Angela ;

Nauwelaerts, Heidi ;

Sessa, Cristiana .

CLINICAL CANCER RESEARCH, 2015, 21 (04) :730-738

[4] Effect of Selumetinib vs Chemotherapy on Progression-Free Survival in Uveal Melanoma A Randomized Clinical Trial [J].

Carvajal, Richard D. ;

Sosman, Jeffrey A. ;

Quevedo, Jorge Fernando ;

Milhem, Mohammed M. ;

Joshua, Anthony M. ;

Kudchadkar, Ragini R. ;

Linette, Gerald P. ;

Gajewski, Thomas F. ;

Lutzky, Jose ;

Lawson, David H. ;

Lao, Christopher D. ;

Flynn, Patrick J. ;

Albertini, Mark R. ;

Sato, Takami ;

Lewis, Karl ;

Doyle, Austin ;

Ancell, Kristin ;

Panageas, Katherine S. ;

Bluth, Mark ;

Hedvat, Cyrus ;

Erinjeri, Joseph ;

Ambrosini, Grazia ;

Marr, Brian ;

Abramson, David H. ;

Dickson, Mark Andrew ;

Wolchok, Jedd D. ;

Chapman, Paul B. ;

Schwartz, Gary K. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2014, 311 (23) :2397-2405

[5] BRAF/NRAS Mutation Frequencies Among Primary Tumors and Metastases in Patients With Melanoma [J].

Colombino, Maria ;

Capone, Mariaelena ;

Lissia, Amelia ;

Cossu, Antonio ;

Rubino, Corrado ;

De Giorgi, Vincenzo ;

Massi, Daniela ;

Fonsatti, Ester ;

Staibano, Stefania ;

Nappi, Oscar ;

Pagani, Elena ;

Casula, Milena ;

Manca, Antonella ;

Sini, MariaCristina ;

Franco, Renato ;

Botti, Gerardo ;

Caraco, Corrado ;

Mozzillo, Nicola ;

Ascierto, Paolo A. ;

Palmieri, Giuseppe .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (20) :2522-2529

[6] Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial [J].

Infante, Jeffrey R. ;

Fecher, Leslie A. ;

Falchook, Gerald S. ;

Nallapareddy, Sujatha ;

Gordon, Michael S. ;

Becerra, Carlos ;

DeMarini, Douglas J. ;

Cox, Donna S. ;

Xu, Yanmei ;

Morris, Shannon R. ;

Peddareddigari, Vijay G. R. ;

Le, Ngocdiep T. ;

Hart, Lowell ;

Bendell, Johanna C. ;

Eckhardt, Gail ;

Kurzrock, Razelle ;

Flaherty, Keith ;

Burris, Howard A., III ;

Messersmith, Wells A. .

LANCET ONCOLOGY, 2012, 13 (08) :773-781

[7] Combined Targeting of BRAF and CRAF or BRAF and PI3K Effector Pathways Is Required for Efficacy in NRAS Mutant Tumors [J].

Jaiswal, Bijay S. ;

Janakiraman, Vasantharajan ;

Kljavin, Noelyn M. ;

Eastham-Anderson, Jeffrey ;

Cupp, James E. ;

Liang, Yuxin ;

Davis, David P. ;

Hoeflich, Klaus P. ;

Seshagiri, Somasekar .

PLOS ONE, 2009, 4 (05)

[8] Prominent role of cyclic adenosine monophosphate signalling pathway in the sensitivity of WTBRAF/WTNRAS melanoma cells to vemurafenib [J].

Krayem, Mohammad ;

Journe, Fabrice ;

Wiedig, Murielle ;

Morandini, Renato ;

Sales, Francois ;

Awada, Ahmad ;

Ghanem, Ghanem .

EUROPEAN JOURNAL OF CANCER, 2014, 50 (07) :1310-1320

[9]

Kurzrock R., 2011, J CLIN ONCOLOGY S, V29, P2011

[10] Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma [J].

Larkin, James ;

Ascierto, Paolo A. ;

Dreno, Brigitte ;

Atkinson, Victoria ;

Liszkay, Gabriella ;

Maio, Michele ;

Mandala, Mario ;

Demidov, Lev ;

Stroyakovskiy, Daniil ;

Thomas, Luc ;

de la Cruz-Merino, Luis ;

Dutriaux, Caroline ;

Garbe, Claus ;

Sovak, Mika A. ;

Chang, Ilsung ;

Choong, Nicholas ;

Hack, Stephen P. ;

McArthur, Grant A. ;

Ribas, Antoni .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (20) :1867-1876

← 1 2 →